Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06444919 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Capsaicin in Digital Osteoarthritis Versus Control

Study acronym: CADOR
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 1, 2024 to Mar 7, 2025
    • Study sites: 1 to 4
    v3
  2. Secondary endpoints: details revised at 5 of 6 entries
    • Study title shortened, about 4 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component. Participants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%). Researchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)
Trial Details
NCT Number NCT06444919
Lead Sponsor University Hospital, Clermont-Ferrand
Collaborators: Grünenthal GmbH
Conditions
(from sponsor)		 Osteoarthritis Hand, Neuropathic Pain
Related terms Neuralgia
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov